| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2885
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7055 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5dfaf0bb046c39cb1b067536822d7e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f7a0ffd6b37f9b8a03d9fba6d91aea2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_536faf538ce8843b30cb076a3ef75321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b35437068a60c48bd75b1a550c0822de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e706b84585cf47d401e32a5ac03e3a8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fdd3e0f302dffbe8c465ae942449b66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19dd3af169547e8da79ea2296c527c0f |
| publicationDate |
2012-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2467159-A1 |
| titleOfInvention |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| abstract |
The invention relates to methods for the treatment of Duchenne muscular dystrophy and to methods for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy. More particularly, the present invention relates to a VLA-4 antagonist for use in the treatment of Duchenne Muscular Dystrophy. The present invention also relates to a method for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy wherein said method comprising a step consisting of determining the level of VLA-4 high T cells in a blood sample obtained from said subject. |
| priorityDate |
2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |